Lupin launches Mesalamine Extended-Release Capsules 0.375 g in US market
Lupin announced the launch of authorized generic version of Bausch Health's Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 19 2020 | 1:41 PM IST